test_document.md

# Sample Medical Document for Testing ResearchTeam

## Introduction

**Daratumumab** is a human monoclonal antibody that targets CD38, a glycoprotein highly expressed on multiple myeloma cells. Clinical studies have demonstrated significant efficacy in treating relapsed and refractory multiple myeloma patients.

## Key Clinical Claims

### Primary Efficacy Findings

The POLLUX study demonstrated that **daratumumab in combination with lenalidomide and dexamethasone significantly improved progression-free survival** compared to lenalidomide and dexamethasone alone (median not reached vs. 18.4 months; HR=0.37; 95% CI: 0.27-0.52; p<0.001).¹

In the CASTOR trial, **daratumumab plus bortezomib and dexamethasone showed superior overall response rates** of 83% versus 63% in the control arm (p<0.001).²

### Safety Profile

**The most common adverse events observed were infusion-related reactions** occurring in approximately 48% of patients during the first infusion, with rates decreasing to less than 5% by the second infusion.³

## Product Information

This study was conducted across multiple countries including **Argentina, Brazil, Chile, and Mexico** for regulatory approval in Latin American markets.

The content is provided in **Spanish** for healthcare professionals in these regions.

## References

1. Dimopoulos MA, Oriol A, Nopoka H, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(14):1319-1331.

2. Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(8):754-766.

3. Safety data from pooled analysis of POLLUX and CASTOR studies. Presented at ASH 2016.

---

**Contact Information:**
Janssen-Cilag Argentina S.A.
Buenos Aires, Argentina
Tel: +54-11-4732-5000

**Important Safety Information:**
Please refer to full prescribing information for complete safety profile and contraindications.